Vitiligo (Leukoderma)
Vitiligo, also known as leukoderma, is a skin condition characterized by the loss of pigment-producing cells, resulting in lighter or white patches on the skin. The patches may appear on different parts of the body, and the extent and progression of the condition vary from person to person.
The supplied Ayurvedic treatment protocol describes an approach using internal medication and external oil application. It emphasizes informing patients about the condition, treatment limitations and expected outcomes, as well as monitoring changes over time.
The source reports promising results and a success rate exceeding 90% with antioxidant tablets. This claim has not been independently verified and should not be interpreted as a guaranteed outcome or established cure rate.
Medicines and Dosages
The following product names and dosage schedules are reproduced from the supplied source for reference. The ingredients, safety, effectiveness and suitability of these products have not been independently verified.
1. Relife Tablets
The supplied source lists the following age-based dosage schedule:
- Children below 3 years: 1-0-1.
- Children aged 3–5 years: 1-1-1.
- Children aged 5–10 years: 2-0-2.
- Children above 10 years and adults: 2-2-2.
These source-stated doses should not be used as a prescription. The age ranges overlap at 5 years, so the original schedule also requires clarification. The product’s ingredients and safety must be reviewed by a qualified healthcare professional before use, particularly in children.
2. Vitilon Oil
Source-stated application: Apply externally to the affected areas. The source describes application followed by sunlight exposure before 8 a.m. It also mentions applying the oil two or three times daily and washing it off with soap. Morning sunlight exposure is described as optional rather than mandatory.
The suitability of the oil and the recommended application frequency should be confirmed with a qualified practitioner. Do not assume that applying the oil makes sunlight exposure safe or beneficial; excessive ultraviolet exposure can cause skin damage, including burns to depigmented areas.
Treatment Duration and Progress Monitoring
The supplied source recommends continuing treatment for a minimum of five years or until the desired results are achieved. This duration has not been independently established as an effective or necessary treatment period. The appropriate plan should be reviewed regularly according to the individual’s response and clinical assessment.
The source also recommends taking photographs periodically to document changes in skin pigmentation. Consistent photographs, taken under similar lighting and conditions, can help track changes over time. Progress should be reviewed with a qualified healthcare professional rather than relying on photographs alone to determine treatment effectiveness.
Important Medical Note
Vitiligo is a chronic condition that can often be managed, although responses to treatment vary. Repigmentation may be possible in some areas, but results are not guaranteed, and the condition may progress or recur.
The product dosages, five-year treatment duration and claim of more than 90% success in the supplied source have not been independently verified. Consult a dermatologist to confirm the diagnosis and discuss established treatment options, potential benefits and risks.
Use particular caution with treatments intended for young children. Do not administer the listed doses to children without medical review, and do not use sunlight exposure as a substitute for professional advice on safe light-based treatment.
